VNA
ITCI

Valley National Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Valley National Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50
Closed -$3K – 1173
2024
Q2 		$3K Buy
50
+15
+43% +$1.04K ﹤0.01% 869
2024
Q1 		$2K Hold
35
– – ﹤0.01% 1007
2023
Q4 		$2K Buy
+35
New +$2.01K ﹤0.01% 1008

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Valley National Advisers's ITCI Position: Q3 2024 in Review

Valley National Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 50 shares — an estimated $3K sold.

Valley National Advisers first reported a position in ITCI in Q4 2023 and held it in 3 quarters. The position peaked at $3K in Q2 2024. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Valley National Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Valley National Advisers sold 50 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $3K.
  • Valley National Advisers first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 3 quarters.
  • Valley National Advisers's Intra-Cellular Therapies Inc. position peaked at $3K in Q2 2024.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Valley National Advisers's 13F filing for Q3 2024, filed 24 Oct 2024.